» Articles » PMID: 17060381

Impaired Regulatory T-cell Response and Enhanced Atherosclerosis in the Absence of Inducible Costimulatory Molecule

Overview
Journal Circulation
Date 2006 Oct 25
PMID 17060381
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Background: T-cell-mediated immunity contributes to the pathogenesis of atherosclerosis, but little is known about how these responses are regulated. We explored the influence of the inducible costimulatory molecule (ICOS) on atherosclerosis and associated immune responses.

Methods And Results: Bone marrow chimeras were generated by transplanting ICOS-deficient or wild-type bone marrow into irradiated atherosclerosis-prone, LDR receptor-deficient mice, and the chimeric mice were fed a high-cholesterol diet for 8 weeks. Compared with controls, mice transplanted with ICOS-deficient marrow had a 43% increase in the atherosclerotic burden, and importantly, their lesions had a 3-fold increase in CD4+ T cells, as well as increased macrophage, smooth muscle cell, and collagen content. CD4+ T cells from ICOS-deficient chimeras proliferated more and secreted more interferon-gamma and tumor necrosis factor-alpha than T cells from control mice, which suggests a lack of regulation. FoxP3+ regulatory T cells (Treg) were found to constitutively express high ICOS levels, which suggests a role for ICOS in Treg function. ICOS-deficient mice had decreased numbers of FoxP3+ Treg and impaired in vitro Treg suppressive function compared with control mice.

Conclusions: ICOS has a key role in regulation of atherosclerosis, through its effect on regulatory T-cell responses.

Citing Articles

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.

Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).

PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.


Local adaptive immunity in atherosclerosis with T cell activation by aortic dendritic cells accelerates pathogenesis.

Zhang W, Cai Z, Ma D, Liu M, Wang J, Sun L iScience. 2024; 27(11):111144.

PMID: 39502289 PMC: 11536043. DOI: 10.1016/j.isci.2024.111144.


Costimulatory and Coinhibitory Immune Checkpoints in Atherosclerosis: Therapeutic Targets in Atherosclerosis?.

Nitz K, Herrmann J, Lerman A, Lutgens E JACC Basic Transl Sci. 2024; 9(6):827-843.

PMID: 39070270 PMC: 11282889. DOI: 10.1016/j.jacbts.2023.12.007.


T-Cell/B-Cell Interactions in Atherosclerosis.

Jones P, Mallat Z, Nus M Arterioscler Thromb Vasc Biol. 2024; 44(7):1502-1511.

PMID: 38813700 PMC: 11208060. DOI: 10.1161/ATVBAHA.124.319845.


Targeting regulatory T cells for cardiovascular diseases.

Wang X, Zhou H, Liu Q, Cheng P, Zhao T, Yang T Front Immunol. 2023; 14:1126761.

PMID: 36911741 PMC: 9995594. DOI: 10.3389/fimmu.2023.1126761.